Details of the Drug

General Information of Drug (ID: DMU8V4S)

Drug Name
Moxifloxacin
Synonyms
Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Peritonitis N.A. Approved [2]
Pneumonic plague N.A. Approved [2]
Septicemic plague N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antibiotics
Affected Organisms
Enteric bacteria and other eubacteria
ATC Code
J01MA14: Moxifloxacin
J01MA: Fluoroquinolones
J01M: QUINOLONE ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
J01MA14: Moxifloxacin
J01MA: Fluoroquinolones
J01M: QUINOLONE ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
S01AE07: Moxifloxacin
S01AE: Fluoroquinolones
S01A: ANTIINFECTIVES
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 401.4
Logarithm of the Partition Coefficient (xlogp) 0.6
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 90% []
Clearance
The clearance of drug is 12 +/- 2 L/h []
Elimination
22% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 11.5 - 15.6 hours [4]
Metabolism
The drug is metabolized via the glucuronide and sulphate conjugation []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.2344 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.6% [4]
Vd
The volume of distribution (Vd) of drug is 1.7-2.7 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 27.5 mg/mL [3]
Chemical Identifiers
Formula
C21H24FN3O4
IUPAC Name
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
InChI
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
InChIKey
FABPRXSRWADJSP-MEDUHNTESA-N
Cross-matching ID
PubChem CID
152946
ChEBI ID
CHEBI:63611
CAS Number
151096-09-2
UNII
U188XYD42P
DrugBank ID
DB00218
TTD ID
D0ZV0Z
VARIDT ID
DR00800
ACDINA ID
D00448
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Modulator [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Moxifloxacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Clarithromycin. Bacterial infection [1A00-1C4Z] [7]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Moxifloxacin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [8]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Telithromycin. Bacterial infection [1A00-1C4Z] [7]
Coadministration of a Drug Treating the Disease Different from Moxifloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [9]
Tretinoin DM49DUI Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Tretinoin. Acne vulgaris [ED80] [10]
Sucralfate DMP9HBO Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Sucralfate. Acne vulgaris [ED80] [11]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Thioguanine. Acute myeloid leukaemia [2A60] [12]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [7]
Uracil mustard DMHL7OB Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Uracil mustard. Acute myeloid leukaemia [2A60] [10]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [7]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Idarubicin. Acute myeloid leukaemia [2A60] [7]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Daunorubicin. Acute myeloid leukaemia [2A60] [7]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Arn-509. Acute myeloid leukaemia [2A60] [7]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [7]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Oliceridine. Acute pain [MG31] [7]
Magnesium Sulfate DMVEK07 Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Magnesium Sulfate. Acute pain [MG31] [11]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Tacrine. Alzheimer disease [8A20] [8]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Galantamine. Alzheimer disease [8A20] [8]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Rivastigmine. Alzheimer disease [8A20] [8]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Donepezil. Alzheimer disease [8A20] [8]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Moxifloxacin and Metronidazole. Amoebiasis [1A36] [9]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Ivabradine. Angina pectoris [BA40] [13]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Bepridil. Angina pectoris [BA40] [7]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Dronedarone. Angina pectoris [BA40] [8]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [7]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [7]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Promazine. Appearance/behaviour symptom [MB23] [7]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Cilostazol. Arterial occlusive disease [BD40] [7]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Voriconazole. Aspergillosis [1F20] [7]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Posaconazole. Aspergillosis [1F20] [7]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Terbutaline. Asthma [CA23] [14]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Pirbuterol. Asthma [CA23] [14]
Isoetharine DMITSEH Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoetharine. Asthma [CA23] [14]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Salbutamol. Asthma [CA23] [15]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Formoterol. Asthma [CA23] [14]
Atomoxetine DM5L6HI Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [7]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [7]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Desipramine. Attention deficit hyperactivity disorder [6A05] [7]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Retigabine. Behcet disease [4A62] [7]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Moxifloxacin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [16]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Loperamide. Bowel habit change [ME05] [17]
Temozolomide DMKECZD Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [10]
Lomustine DMMWSUL Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [10]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Eribulin. Breast cancer [2C60-2C6Y] [7]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [7]
Mitomycin DMH0ZJE Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitomycin. Breast cancer [2C60-2C6Y] [10]
Thiotepa DMIZKOP Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [10]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Tamoxifen. Breast cancer [2C60-2C6Y] [7]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Toremifene. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Bosutinib. Breast cancer [2C60-2C6Y] [7]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Sotalol. Cardiac arrhythmia [BC9Z] [7]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [7]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [14]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [18]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [14]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [14]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [14]
Phenylbutazone DMAYL0T Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Phenylbutazone. Chronic pain [MG30] [19]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Moxifloxacin and Ketoprofen. Chronic pain [MG30] [19]
Irinotecan DMP6SC2 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Irinotecan. Colorectal cancer [2B91] [10]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Oxaliplatin. Colorectal cancer [2B91] [7]
Capecitabine DMTS85L Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [10]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoproterenol. Conduction disorder [BC63] [14]
Mestranol DMG3F94 Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [20]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Halothane. Corneal disease [9A76-9A78] [7]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Propofol. Corneal disease [9A76-9A78] [21]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Sevoflurane. Corneal disease [9A76-9A78] [7]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Probucol. Coronary atherosclerosis [BA80] [7]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Methadone. Cough [MD12] [8]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Clofazimine. Crohn disease [DD70] [7]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [22]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Mifepristone. Cushing syndrome [5A70] [8]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Pasireotide. Cushing syndrome [5A70] [7]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Osilodrostat. Cushing syndrome [5A70] [7]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimipramine. Depression [6A70-6A7Z] [7]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Imipramine. Depression [6A70-6A7Z] [7]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluoxetine. Depression [6A70-6A7Z] [7]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Nortriptyline. Depression [6A70-6A7Z] [7]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Escitalopram. Depression [6A70-6A7Z] [8]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Clomipramine. Depression [6A70-6A7Z] [7]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Trazodone. Depression [6A70-6A7Z] [7]
Amitriptyline DMK7F9S Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Amitriptyline. Depression [6A70-6A7Z] [7]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Amoxapine. Depression [6A70-6A7Z] [7]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Mirtazapine. Depression [6A70-6A7Z] [7]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Protriptyline. Depression [6A70-6A7Z] [7]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxepin. Depression [6A70-6A7Z] [7]
Venlafaxine DMR6QH0 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Venlafaxine. Depression [6A70-6A7Z] [7]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [7]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Deutetrabenazine. Dystonic disorder [8A02] [7]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Cannabidiol. Epileptic encephalopathy [8A62] [13]
Mefenamic acid DMK7HFI Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Mefenamic acid. Female pelvic pain [GA34] [19]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Solifenacin. Functional bladder disorder [GC50] [7]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Pentamidine. Fungal infection [1F29-1F2F] [7]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ketoconazole. Fungal infection [1F29-1F2F] [7]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [7]
Procarbazine DMIK367 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [10]
Bleomycin DMNER5S Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Bleomycin. Hodgkin lymphoma [2B30] [10]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [7]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [7]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [23]
Didanosine DMI2QPE Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [24]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [7]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [7]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [25]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Moxifloxacin and Mipomersen. Hyper-lipoproteinaemia [5C80] [26]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Moxifloxacin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [8]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Moxifloxacin and BMS-201038. Hyper-lipoproteinaemia [5C80] [27]
Quinapril DMR8H31 Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [13]
Fludrocortisone DMUDIR8 Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [28]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [29]
Melatonin DMKWFBT Minor Decreased metabolism of Moxifloxacin caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [9]
Iron DMAP8MV Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [30]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [8]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Phenolphthalein. Irritable bowel syndrome [DD91] [8]
DTI-015 DMXZRW0 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by DTI-015. Liver cancer [2C12] [10]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Crizotinib. Lung cancer [2C25] [31]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Porfimer Sodium. Lung cancer [2C25] [32]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ceritinib. Lung cancer [2C25] [8]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [10]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Osimertinib. Lung cancer [2C25] [7]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Selpercatinib. Lung cancer [2C25] [7]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lumefantrine. Malaria [1F40-1F45] [9]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Halofantrine. Malaria [1F40-1F45] [33]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [7]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Quinine. Malaria [1F40-1F45] [7]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Primaquine. Malaria [1F40-1F45] [7]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Mefloquine. Malaria [1F40-1F45] [7]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [7]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [34]
Fludarabine DMVRLT7 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [10]
Pentostatin DM0HXDS Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Pentostatin. Mature B-cell leukaemia [2A82] [10]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Idelalisib. Mature B-cell leukaemia [2A82] [35]
Chlorambucil DMRKE63 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Chlorambucil. Mature B-cell leukaemia [2A82] [10]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [36]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Clofarabine. Mature B-cell lymphoma [2A85] [37]
Vincristine DMINOX3 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vincristine. Mature B-cell lymphoma [2A85] [10]
Teniposide DMLW57T Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Teniposide. Mature B-cell lymphoma [2A85] [10]
Mercaptopurine DMTM2IK Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [10]
Cytarabine DMZD5QR Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [10]
Mechlorethamine DM0CVXA Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [10]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Vemurafenib. Melanoma [2C30] [8]
Dacarbazine DMNPZL4 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [10]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and LGX818. Melanoma [2C30] [7]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [20]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Moxifloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [8]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Moxifloxacin and Thalidomide. Multiple myeloma [2A83] [9]
Melphalan DMOLNHF Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [10]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Siponimod. Multiple sclerosis [8A40] [9]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ozanimod. Multiple sclerosis [8A40] [7]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Deflazacort. Muscular dystrophy [8C70] [28]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Methoxsalen. Mycosis fungoides [2B01] [9]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Romidepsin. Mycosis fungoides [2B01] [7]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [7]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [10]
Busulfan DMXYJ9C Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [10]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Droperidol. Nausea/vomiting [MD90] [8]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Prochlorperazine. Nausea/vomiting [MD90] [7]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Promethazine. Nausea/vomiting [MD90] [7]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Palonosetron. Nausea/vomiting [MD90] [7]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Granisetron. Nausea/vomiting [MD90] [7]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Dolasetron. Nausea/vomiting [MD90] [7]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ondansetron. Nausea/vomiting [MD90] [7]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Bupropion. Nicotine use disorder [6C4A] [38]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Entrectinib. Non-small cell lung cancer [2C25] [7]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomethadyl Acetate. Opioid use disorder [6C43] [13]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lofexidine. Opioid use disorder [6C43] [7]
Rofecoxib DM3P5DA Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Rofecoxib. Osteoarthritis [FA00-FA05] [19]
Valdecoxib DMAY7H4 Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Valdecoxib. Osteoarthritis [FA00-FA05] [19]
Diclofenac DMPIHLS Moderate Additive CNS depression effects by the combination of Moxifloxacin and Diclofenac. Osteoarthritis [FA00-FA05] [19]
Naproxen DMZ5RGV Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Naproxen. Osteoarthritis [FA00-FA05] [19]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Rucaparib. Ovarian cancer [2C73] [7]
Altretamine DMKLAYG Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Altretamine. Ovarian cancer [2C73] [10]
Topotecan DMP6G8T Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [10]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Dextropropoxyphene. Pain [MG30-MG3Z] [7]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Aspirin. Pain [MG30-MG3Z] [29]
Etodolac DM6WJO9 Moderate Additive CNS depression effects by the combination of Moxifloxacin and Etodolac. Pain [MG30-MG3Z] [19]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Moxifloxacin and Diflunisal. Pain [MG30-MG3Z] [19]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Moxifloxacin and Ibuprofen. Pain [MG30-MG3Z] [19]
Nabumetone DMAT2XH Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Nabumetone. Pain [MG30-MG3Z] [19]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Buprenorphine. Pain [MG30-MG3Z] [7]
Piroxicam DMTK234 Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Piroxicam. Pain [MG30-MG3Z] [19]
Streptozocin DMOF7AT Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Streptozocin. Pancreatic cancer [2C10] [10]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Triclabendazole. Parasitic worm infestation [1F90] [7]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimavanserin. Parkinsonism [8A00] [7]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Lindane. Pediculosis [1G00] [39]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Famotidine. Peptic ulcer [DA61] [9]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [40]
Prednisone DM2HG4X Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisone. Postoperative inflammation [1A00-CA43] [28]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [19]
Betamethasone DMAHJEF Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Betamethasone. Postoperative inflammation [1A00-CA43] [28]
Hydrocortisone DMGEMB7 Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [28]
Ketorolac DMI4EL5 Moderate Additive CNS depression effects by the combination of Moxifloxacin and Ketorolac. Postoperative inflammation [1A00-CA43] [19]
Bromfenac DMKB79O Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Bromfenac. Postoperative inflammation [1A00-CA43] [19]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ritodrine. Preterm labour/delivery [JB00] [14]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Degarelix. Prostate cancer [2C82] [7]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Nilutamide. Prostate cancer [2C82] [7]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Relugolix. Prostate cancer [2C82] [7]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Bicalutamide. Prostate cancer [2C82] [7]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Alfuzosin. Prostate hyperplasia [GA90] [7]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Verteporfin. Psoriasis [EA90] [13]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomepromazine. Psychotic disorder [6A20-6A25] [7]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluphenazine. Psychotic disorder [6A20-6A25] [7]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Triflupromazine. Psychotic disorder [6A20-6A25] [7]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Sorafenib. Renal cell carcinoma [2C90] [7]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Salsalate. Rheumatoid arthritis [FA20] [19]
Meloxicam DM2AR7L Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Meloxicam. Rheumatoid arthritis [FA20] [19]
Sulindac DM2QHZU Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Sulindac. Rheumatoid arthritis [FA20] [19]
Celecoxib DM6LOQU Moderate Additive CNS depression effects by the combination of Moxifloxacin and Celecoxib. Rheumatoid arthritis [FA20] [19]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Oxaprozin. Rheumatoid arthritis [FA20] [19]
Flurbiprofen DMGN4BY Moderate Additive CNS depression effects by the combination of Moxifloxacin and Flurbiprofen. Rheumatoid arthritis [FA20] [19]
Fenoprofen DML5VQ0 Moderate Additive CNS depression effects by the combination of Moxifloxacin and Fenoprofen. Rheumatoid arthritis [FA20] [19]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [28]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Moxifloxacin and Leflunomide. Rheumatoid arthritis [FA20] [8]
Indomethacin DMSC4A7 Moderate Additive CNS depression effects by the combination of Moxifloxacin and Indomethacin. Rheumatoid arthritis [FA20] [19]
Tolmetin DMWUIJE Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Tolmetin. Rheumatoid arthritis [FA20] [19]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Mesoridazine. Schizophrenia [6A20] [8]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Thioridazine. Schizophrenia [6A20] [8]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Aripiprazole. Schizophrenia [6A20] [9]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Iloperidone. Schizophrenia [6A20] [8]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Paliperidone. Schizophrenia [6A20] [7]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Haloperidol. Schizophrenia [6A20] [8]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Perphenazine. Schizophrenia [6A20] [7]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Chlorpromazine. Schizophrenia [6A20] [7]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Clozapine. Schizophrenia [6A20] [7]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Trifluoperazine. Schizophrenia [6A20] [7]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ziprasidone. Schizophrenia [6A20] [8]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Risperidone. Schizophrenia [6A20] [7]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Moxifloxacin and Olanzapine. Schizophrenia [6A20] [9]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Amisulpride. Schizophrenia [6A20] [7]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Asenapine. Schizophrenia [6A20] [7]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimozide. Schizophrenia [6A20] [13]
Salicyclic acid DM2F8XZ Moderate Additive CNS stimulant effects by the combination of Moxifloxacin and Salicyclic acid. Seborrhoeic dermatitis [EA81] [29]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Vardenafil. Sexual dysfunction [HA00-HA01] [7]
Floxuridine DM04LR2 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Floxuridine. Solid tumour/cancer [2A00-2F9Z] [10]
Dactinomycin DM2YGNW Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [10]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [28]
Cyclophosphamide DM4O2Z7 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [10]
Vinblastine DM5TVS3 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinblastine. Solid tumour/cancer [2A00-2F9Z] [10]
Ifosfamide DMCT3I8 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [10]
Docetaxel DMDI269 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [10]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [13]
Mitoxantrone DMM39BF Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [10]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Moxifloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [7]
Etoposide DMNH3PG Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Etoposide. Solid tumour/cancer [2A00-2F9Z] [10]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [7]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [28]
Cisplatin DMRHGI9 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cisplatin. Solid tumour/cancer [2A00-2F9Z] [10]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [41]
Gemcitabine DMSE3I7 Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [10]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [7]
Fluorouracil DMUM7HZ Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [10]
Taxol DMUOT9V Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [10]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [7]
Vinorelbine DMVXFYE Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [10]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Pitolisant. Somnolence [MG42] [7]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [7]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Moxifloxacin and Naltrexone. Substance abuse [6C40] [42]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [8]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Adenosine. Supraventricular tachyarrhythmia [BC81] [43]
Plicamycin DM7C8YV Minor Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [10]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Anagrelide. Thrombocytosis [3B63] [7]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Lenvatinib. Thyroid cancer [2D10] [7]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Cabozantinib. Thyroid cancer [2D10] [7]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Papaverine. Tonus and reflex abnormality [MB47] [44]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Tizanidine. Tonus and reflex abnormality [MB47] [7]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [22]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Tacrolimus. Transplant rejection [NE84] [7]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Astemizole. Vasomotor/allergic rhinitis [CA08] [7]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [7]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Disopyramide. Ventricular tachyarrhythmia [BC71] [7]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Procainamide. Ventricular tachyarrhythmia [BC71] [7]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [7]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Moxifloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [7]
⏷ Show the Full List of 272 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Moxifloxacin 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 Moxifloxacin FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
8 Canadian Pharmacists Association.
9 Cerner Multum, Inc. "Australian Product Information.".
10 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
11 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
12 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
15 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
16 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
18 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
19 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
20 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
21 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
22 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
23 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
24 Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
25 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
26 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
27 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
29 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
30 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
31 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
33 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
34 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
35 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
36 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
37 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
38 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
39 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
40 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
41 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
43 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
44 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]